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In order to grow beyond minimal size and to metas-
tasize, tumors need to induce the growth of new
blood vessels (angiogenesis). Whereas in normal tis-
sues, vascular quiescence is maintained by the domi-
nant in¯uence of endogenous angiogenesis inhibitors
over angiogenic stimuli, tumor angiogenesis is
induced by increased secretion of angiogenic factors
and/or by downregulation of angiogenesis inhibitors.
Recent evidence suggests vascular endothelial growth
factor (VEGF) as the major tumor angiogenesis fac-
tor, promoting tumor growth, invasion, and metas-
tasis. Conversely, blocking of VEGF function inhibits
angiogenesis and suppresses tumor growth in vivo.
Newly identi®ed members of the VEGF family of
angiogenesis factors include placental growth factor,
VEGF-B, VEGF-C, and VEGF-D, and show overlap-
ping binding patterns to speci®c endothelial cell
receptors. VEGF-C appears to play a major role as a
lymphangiogenesis factor and as a growth factor for
Kaposi's sarcoma. In contrast, endogenous inhibitors
prevent blood vessel growth in normal tissues. In
particular, thrombospondin-1 (TSP-1) and TSP-2
are expressed in normal skin and, when introduced
into squamous cell carcinomas, potently inhibit
malignant tumor growth via inhibition of tumor
angiogenesis. Key words: skin/TSP-1/TSP-2/VEGF.
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A
ngiogenesis, the growth of new capillaries from pre-
existing blood vessels, is essential for cancers to grow
beyond minimal size (Folkman, 1992), providing a
lifeline for tumor sustenance and waste disposal. It
has been suggested that expression of an angiogenic
phenotype may even precede the development of other traits that
contribute to the malignant phenotype (``angiogenic switch'')
(Hanahan and Folkman, 1996), and there is convincing evidence
that therapeutic inhibition of angiogenesis leads to inhibition of
tumor growth and metastatic spread in several mouse tumor models
(O'Reilly et al, 1994, 1997; Folkman, 1997). Angiogenesis is a
complex multistep process involving extravasation of plasma
proteins, degradation of extracellular matrix, endothelial cell
migration and proliferation, and capillary tube formation. Recent
advances in vascular biology have identi®ed some of the key factors
that control vascular growth, and have led to the concept that in
normal tissues, vascular quiescence is maintained by the dominant
in¯uence of endogenous angiogenesis inhibitors over angiogenic
stimuli, whereas tumor angiogenesis is induced by increased
secretion of angiogenic factors and/or by downregulation of
angiogenesis inhibitors. The following review identi®es some of
the major mediators involved in the control of tumor angiogenesis
and presents evidence for an important role of the non-neoplastic
tumor stroma in the control of tumor growth and invasion.
VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF)
Vascular endothelial growth factor (VEGF) is regarded as the major
tumor angiogenesis factor during epithelial carcinogenesis, in a
large number of malignant human cancers, and in tumor metastases
(Brown et al, 1997; Dvorak et al, 1995). Originally identi®ed as a
tumor cell-derived factor that induced vascular hyperpermeability
to plasma proteins (Senger et al, 1983) and therefore named vascular
permeability factor, subsequent studies characterized VEGF as an
endothelial cell-speci®c mitogen. VEGF is a homodimeric,
heparin-binding glycoprotein occurring in at least four isoforms
of 121, 165, 189, and 201 amino acids, due to alternative splicing
(Houck et al, 1991; Tischer et al, 1991). VEGF binds to two type III
tyrosine kinase receptors on vascular endothelial cells, Flt-1/VEGF
receptor-1 (VEGFR-1) and KDR/Flk-1/VEGFR-2 (Terman et al,
1991; deVries et al, 1992; Quinn et al, 1993). Moreover, VEGF165
additionally binds to the neuropilin receptor on endothelial and
other cells (Soker et al, 1996). In vivo, VEGF enhances
microvascular permeability (Senger et al, 1983) and angiogenesis
(Connolly et al, 1989; Leung et al, 1989; Claffey et al, 1996; Detmar
et al, 1998). The importance of VEGF in promoting angiogenesis
and vascular permeability in vivo was recently con®rmed in a
transgenic mouse model, using the human keratin 14 promoter to
target selective overexpression of the murine VEGF gene to basal
epidermal keratinocytes and follicular outer root sheath keratino-
cytes (Detmar et al, 1998). VEGF transgenic mice display markedly
enhanced skin vascularization with increased numbers of tortuous
and leaky blood vessels.
The majority of human cancers studied are characterized by
overexpression of VEGF by tumor cells and by overexpression of
VEGF receptors on tumor-associated blood vessels (Dvorak et al,
1995). Blocking of VEGF function inhibits angiogenesis and
suppresses tumor growth in vivo (Kim et al, 1993; Millauer et al,
1994, 1996; Warren et al, 1995; Cheng et al, 1997), and antibody
inhibition of the VEGF receptor Flk-1 prevented tumor cell
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invasion in vivo (Skobe et al, 1997). Tumor cell VEGF expression is
induced by at least three distinct molecular pathways: (1) Tumor-
secreted growth factors such as transforming growth factor-a
directly stimulate tumor growth in an autocrine loop and,
simultaneously, induce secretion of tumor-derived VEGF, acting
± in a paracrine way ± as a potent pro-angiogenic factor to recruit
stromal blood vessels into the tumor for enhanced nutritional
support (Detmar et al, 1994). (2) Hypoxia directly induces tumor
cell expression of VEGF, increasing both VEGF gene transcription
and mRNA stability (Detmar et al, 1997; Claffey et al, 1998). The
importance of this mechanism is demonstrated by the high VEGF
expression in malignant tissue in the immediate vicinity of tumor
necroses. (3) Oncogenes are directly involved in the control of
VEGF expression, with a prominent inductive role of the ras
oncogene and a suppressive function of the p53 tumor suppressor
gene (Grugel et al, 1995; Kieser et al, 1994).
OTHER VEGF FAMILY MEMBERS
Within the last few years, several additional members of the VEGF
family of angiogenesis factors have been identi®ed. Placental
growth factor (PlGF) and VEGF-B bind to the VEGF receptors
Flt1 and neuropilin (Fig 1), whereas VEGF-C and VEGF-D bind
to KDR and, in addition, to the recently identi®ed Flt4 receptor
that is predominantly expressed on lymphatic endothelium,
suggesting an important role in lymphangiogenesis. Indeed,
overexpression of VEGF-C in the skin of transgenic mice resulted
in an increased number of enlarged cutaneous lymphatic vessels,
but not blood vessels (Jeltsch et al, 1997). Whereas little is known
about the expression and biologic activity of PlGF and VEGF-B in
malignant tumors, we have recently identi®ed VEGF-C as a novel
growth factor for AIDS-associated Kaposi's sarcoma (Skobe et al,
1999). Moreover, we found strong expression of both VEGF-C
receptors, KDR and Flt4, on spindle-shaped Kaposi's sarcoma cells
in situ, suggesting that the tumor cells of Kaposi's sarcomas are of
lymphatic rather than blood vessel origin and/or differentiation
(Jussila et al, 1998; Skobe et al, 1999). These ®ndings identify Flt4 as
a novel molecular marker for Kaposi's sarcomas and may yield new
insights into the histogenetic differentiation of this tumor. There is
increasing evidence that tumor cell expression of VEGF-C (and,
possibly, VEGF-D) might be related to the metastatic risk of several
human cancers; however, the direct biologic roles of VEGF-C and
VEGF-D for tumor growth and tumor (lymph)angiogenesis have
remained largely elusive.
THROMBOSPONDIN-1 (TSP-1)
In contrast to the large number of reports on tumor angiogenesis
factors, much less is known about the expression and the biologic
role of endogenous inhibitors of angiogenesis during carcinogen-
esis, tumor growth, and tumor metastasis. Several naturally
occuring inhibitors of tumor angiogenesis have been identi®ed
(Table I), including thrombospondin-1 (TSP-1) (Weinstat-Saslow
et al, 1994), angiostatin (O'Reilly et al, 1994), endostatin (O'Reilly
et al, 1997), vasostatin (Pike et al, 1998), and thrombospondin-2
(Streit et al, 1999), and they have been shown to inhibit tumor
growth and tumor angiogenesis in several experimental models of
human tumor xenotransplants in immunode®cient mice. Despite
this proven antitumoral activity in mouse models, the mechanisms
of action of these endogenous inhibitors have remained largely
unknown.
TSP-1 is a member of a family of matricellular proteins (TSP-1
to TSP-5) that are encoded by separate genes (Bornstein, 1992).
TSPs play an important role in a variety of biologic processes,
including cell±cell and cell±matrix interactions. TSP-1 is a 450 kDa
homotrimeric glycoprotein that regulates attachment, proliferation,
migration, and differentiation of various cell types (for review, see
Bornstein, 1995). TSP-1 inhibits proliferation and migration of
vascular endothelial cells in vitro and inhibits neovascularization in
vivo, contributing to the normal quiescence of the vasculature
(Tolsma et al, 1993). TSP-1 expression was inversely correlated
with malignant progression in human lung, breast, and bladder
carcinoma cell lines (Zabrenetzky et al, 1994; Campbell et al, 1998).
In human skin, TSP-1 is deposited in the dermo±epidermal
basement membrane (Wight et al, 1985), contributing to the
antiangiogenic barrier that separates the avascular epidermis from
the vascularized dermis. Recently, we found that TSP-1 expression
was downregulated in squamous cell carcinomas (SCC) of the skin,
as compared with normal skin. Based on these ®ndings, we studied
the biologic role of TSP-1 for cutaneous carcinoma growth, using
stably transfected A431 or SCC-13 squamous cell carcinoma cells in
an intradermal xenograft model (Streit et al, 1999). These
investigations demonstrated that TSP-1 overexpression signi®cantly
reduced intradermal tumor growth of A431 squamous cell
carcinoma cells and completely inhibited tumor formation of the
slowly growing squamous cell carcinoma cell line SCC-13. TSP-1
Figure 1. Overlapping binding patterns of members of the VEGF
family of angiogenesis factors to endothelial cell VEGF receptors
(VEGFR).
Figure 2.TSP-2 is expressed in normal human skin. Immunohisto-
chemical detection of TSP-2 in the basal layer of normal epidermis (A) and
absence of TSP-2 immunoreactivity in invasive cutaneous squamous cell
carcinoma (B). Immunohistochemistry was performed as described in Streit
et al (1999).
Table I. Endogenous inhibitors of tumor angiogenesis
Year Inhibitor Fragment of MW Authors
1994 thrombospondin-1 ± 450 kDa Weinstat-Saslow et al
1994 angiostatin plasminogen 38 kDa O'Reilly et al
1997 endostatin collagen
XVIII
20 kDa O'Reilly et al
1998 vasostatin calreticulin ~ 30 kDa Pike et al
1999 thrombospondin-2 ± 450 kD Streit et al
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overexpressing A431 tumors were characterized by extensive areas
of necrosis and by decreased tumor vessel numbers and sizes, clearly
demonstrating its antiangiogenic activity. Several lines of evidence
suggest that the antitumoral effects of TSP-1 are predominantly
mediated through interaction with vascular endothelium, with little
or no direct activity on tumor cell growth. In vitro, TSP-1 did not
affect anchorage-dependent tumor cell growth in monolayer
culture or anchorage-independent cell growth in soft agar colony
forming assays, and TSP-1 did not increase tumor cell susceptibility
to induction of apoptosis (Streit et al, 1999). Moreover, we did not
detect any changes in the rate of cell proliferation in TSP-1
overexpressing A431 tumors in vivo. The mechanisms of TSP-1's
antiangiogenic activity are the subject of ongoing research.
Interaction of the CSVTCG sequence contained within TSP-1's
type I repeats with the CD36 receptor on endothelial cells has been
reported to induce endothelial cell apoptosis (Tolsma et al, 1993;
Volpert et al, 1995; Dawson et al, 1997). Moreover, distinct
heparin-binding sequences within the TSP-1 type I repeats have
been identi®ed that inhibit endothelial cell migration in vitro
(Iruela-Arispe et al, 1999). Recent evidence also suggests an
important role of the RFK sequence, contained within the type I
repeats, as a physiologic mediator of TGF-b activation. Whereas
several of the abnormalities found in TSP-1 de®cient mice could be
normalized by administration of a TGF-b activating synthetic
peptide (Crawford et al, 1998), it remains to be established whether
and to what extent activation of TGF-b is also involved in the
antitumoral activity of TSP-1.
THROMBOSPONDIN-2 (TSP-2)
TSP-2 is a 450 kDa trimeric, modular glycoprotein that has a
considerable structural similarity with TSP-1 (Bornstein et al,
1991). Similar to TSP-1, TSP-2 is secreted as a disul®de-bonded
homotrimer (Bornstein, 1992) and interacts with several cell surface
receptors, including the integrin avb3, low-density lipoprotein-
related receptor protein, and heparan sulfate proteoglycans (Chen
et al, 1994, 1996). The expression of TSP-2 is spatially and
temporally different from TSP-1 during embryonic development
and in adult tissues, with predominant TSP-2 expression in areas of
chondrogenesis and in early connective tissues (Iruela-Arispe et al,
1993; Kyriakides et al, 1998). Moreover, the regulation of TSP-2
gene expression by growth factors and hormones is distinct from
TSP-1 (Bornstein et al, 1991; Lafeuillade et al, 1996). Previously,
TSP-2 was reported to diminish the angiogenic activity of basic
®broblast growth factor (Volpert et al, 1995) and the formation of
focal adhesions in aortic endothelial cells (Murphy-Ullrich et al,
1993). Mice de®cient in TSP-2 were characterized, among other
abnormalities, by increased numbers of blood vessels in several
tissues including the skin (Kyriakides et al, 1998), suggesting a role
of TSP-2 in the control of blood vessel growth.
Recently, we found that TSP-2 mRNA is expressed in basal
epidermal keratinocytes and that TSP-2 protein is found in the basal
epidermal layer as well as in the dermal±epidermal basement
membrane area (Fig 2). TSP-2 probably contributes to the anti-
angiogenic barrier function that prevents vessel ingrowth into the
epidermis. It is of interest that we found both TSP-2 mRNA and
protein expression to be downregulated in invasive human squamous
cell carcinomas (SCC) of the skin, lesions that are characterized by
richly angiogenic stroma (Fig 2). These ®ndings suggested a
protective role of TSP-2 that is lost during carcinogenesis. To test
this hypothesis, we stably overexpressed TSP-2 in human A431
squamous cell carcinoma cells, either alone or in combination with
the related inhibitor TSP-1. Indeed, we found a potent, more than
90% inhibition of in vivo tumor growth by TSP-2 (Streit et al, 1999),
most likely caused by the potent inhibition of tumor vascularization
that was observed in TSP-2 expressing tumors. The TSP-2 mediated
antitumoral effect was signi®cantly more potent than the effect of
TSP-1 that resulted in tumor growth inhibition of approximately
50%. Importantly, when TSP-2 was coexpressed with TSP-1, tumor
development was completely inhibited over an observation period of
up to 3 months, suggesting that combinations of angiogenesis
inhibitors might have additive or synergistic antitumoral effects (Streit
et al, 1999). Our results also suggest that the expression of TSP-2 in
normal tissues exerts a protective effect against tumor development,
and that re-introduction of TSP-2 into malignant tumor cells or
treatment of tumors with exogenous TSP-2 or TSP-2 derived
fragments might be a promising new approach for the treatment of
human cancers and/or their metastases.
The molecular mechanisms of TSP-2 mediated inhibition of
tumor angiogenesis and the molecular domain(s) responsible
remain to be established. Similar to TSP-1, the TSP-2 protein
also contains two CSVTCG sequences within the type I repeats
that bind to the CD36 receptor on endothelial cells; however, in
contrast to TSP-1, TSP-2 lacks the TGF-b-activating sequence
RFK. Because the in vivo activity of TSP-2 appears to be more
potent than that of TSP-1, as demonstrated by the more
pronounced effects in tumor assays and in TSP-2 versus TSP-1
de®cient mice, it is likely that additional sequences within the TSP-
2 molecule are involved in the mediation of its angio-inhibitory
activity. Using both recombinant fragments of human TSP-2 and
synthetic peptides derived from the human TSP-2 sequence, we
currently aim to identify additional bioactive domains within the
human TSP-2 molecule.
CONTROL OF MALIGNANT TUMOR GROWTH AND
INVASION BY TUMOR STROMA
Recent studies provide compelling evidence for a much more
active role of the tumor stroma (nonmalignant mesenchymal cells
in the vicinity of the tumor, including ®broblasts and endothelial
cells) in the control of tumor progression and invasion than
generally anticipated. Indeed, it appears that stromal cells are
essential to provide the matrix needed for tumor invasion, and that
inhibition of distinct stromal functions might prevent cancer
progression. In 1997, Skobe et al demonstrated that inhibition of
¯k-1 (VEGFR-2), a VEGF receptor selectively expressed on
endothelial cells, was suf®cient to inhibit tumor invasion of
malignant, transformed epidermal keratinocytes, despite the main-
tenance of tumor cell proliferation (Skobe et al, 1997). More
recently, we have shown that overexpression of VEGF in tumor
cells, leading to selective induction of tumor angiogenesis and
vascular hyperpermeability, was suf®cient to induce invasiveness,
including single cell invasion, of SCC-13 squamous cell carcinomas
that are normally noninvasive after intradermal injection into nude
mice (Detmar et al 2000).
It was previously shown that ras-transduced epidermal kerati-
nocytes, isolated from the skin of newborn mice, had the capacity
to form malignant, invasive squamous cell carcinomas after
transplantation onto mouse skin, using a silicone transplantation
chamber technique (Dotto et al, 1988). When normal dermal
®broblasts were admixed with these ras-transduced keratinocytes,
squamous cell carcinoma development was inhibited. The exact
molecular mechanisms responsible for this inhibitory effect have
remained unknown; however, our recent studies show pronounced
expression of TSP-1 and TSP-2 also by dermal ®broblasts in vitro
and in vivo. Therefore, the inhibitory effect of normal ®broblasts on
tumor growth might be due, at least in part, to the secretion of
endogenous angiogenesis inhibitors by ®broblasts, resulting in
inhibition of tumor growth and angiogenesis. Currently, we are
investigating this hypothesis using genetic mouse models for
transgenic overexpression or for de®ciency of TSP-1 and TSP-2.
In summary, increasing evidence suggests that the creation of an
angiogenic stroma is required for tumor progression and invasion
and that inhibition of angiogenesis, in addition to its effects on the
growth and metastasis of established tumors, might also affect the
early steps of tumor development.
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